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Head and neck cancer presents the greatest impairment to quality of
life of any malignancy and its management is highly resource-inten-
sive. Despite this, retrospective evidence suggests that the organiza-
tion of care for these patients in the UK is significantly flawed. A
recent questionnaire study showed great disparity in practice
between individual clinicians (Edwards et al, 1999), while a more
recent retrospective study by the same group showed that 40% of
patients in three UK regions received non-standard treatment
(Edwards and Johnson, 1999). We used a formal nominal group
method to establish standards for the process of care (Birchall, 1997;
1998). These standards have since been included in a consensus
document agreed by the members of the British Association of
Otorhinolaryngologists, Head and Neck Surgeons, which gives guid-
ance for the management of patients with head and neck cancer
(Wilson, 1998b; Wilson 1998c; Wilson, 2000). We then tested stan-
dards for the first part of the process of care by 1-year prospective
regional audit. The aim of the study was to obtain an accurate picture
of performance across a wide range of hospitals, to obtain bench-
marking data and to allow analysis of the ‘patient journey’ through
from diagnosis to completion of care for head and neck cancers.
METHODS
Patients
To prevent patient selection bias, the audit was population-based.
All residents of the South and West region (population 6.5 million)
diagnosed with a primary head and neck cancer in the period 1
December 1996 to 30 November 1997 were included. Cancers of
skin, thyroid and lip were excluded, as were histologically proven
cases of melanoma and lymphoma. Cases were identified by
monthly downloads of pathology reports or by clinician reporting
using standard proformas developed and piloted by the Tumour
Panel. Staging used the UICC TNM system (UICC, 1997).
Outcome measures
This study examined that part of the process before treatment.
Primary outcome measures were numbers of cases presenting and
treated by individual clinicians and Trusts, proportions of tumours
staged and proportions of patients receiving a chest X-ray and being
seen in a multidisciplinary clinic pretreatment. Secondary outcome
measures were times between activities in the process of care,
proportions of patients with advanced (T3/T4 stage) tumours
receiving computerized tomographic (CT) or magnetic resonance
imaging (MRI) scans, numbers of patients invited/recruited into clin-
ical trials and numbers completing quality-of-life measurements.
Data protection and assurance
Data was protected by a strict Security and Confidentiality Policy
conforming to current conventions (Department of Health, 1996).
Internal audit and peer-review methods were used to ensure accu-
racy and validity of information, supplemented by computerized
validation checks. Comparison with the Cancer Register was used
to ensure all cases were identified. A final quality-check was
achieved by sampling notes corresponding to returned forms in
three randomly-chosen centres.
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Forms were received for 566 cases. A further 61 possible cases
were identified by pathology reports, but found to be outside the
audit on examination of hospital notes. Completeness of informa-
tion exceeded 80% in most categories. However, performance
status recording was low (23%). 359 (64%) of patients were male.
86% of patients with glottic cancer were male, while oral cavity
cancers split 56% male: 44% female. Females tended to present
later. The age group 45–64 years tended to contain more advanced
stage tumours than those aged over 65 years. Total numbers by site
were: larynx 179; oral cavity 170; pharynx 119; salivary 50; other
sites 48.
Numbers of patients referred and treated per Hospital Trust
were (median and range) 21 (1–58) and 9 (1–65) respectively
(Table 1). Three hospital Trusts (11%) treated more than 50 new
patients, while 16 (57%) treated less than 20. The number of
Trusts listed exceeds those participating in the audit since a few
patients were referred for treatment to Trusts outside the region
(e.g. London). In addition, six patients (1%) were treated in private
hospitals and these have been grouped together.
The mean proportion of patients staged (standard 100%) was
88% (larynx), 88% (oral cavity) and 74% (other), with overall
mean being 83%. Overall, 59% of patients received a pretreatment
chest X-ray (standard 95%, Table 2). For advanced (T3/T4)
tumours, the mean percentage receiving MRI or CT-scan was:
larynx 55% (range 0–100, standard 90%); oral cavity 57% (range
0–100, standard 90%); ear/nose/sinus 44% (range 0–100, standard
100%) (Table 2).
45% of patients were seen in a multidisciplinary clinic pretreat-
ment (range 15–88%; standard 95%), and this was proportional to
the frequency of clinics held (c2
3 = 17.4; P = 0.00017) (Figure 1).
The median number of cases treated per surgeon was four (range
1–26) (Figure 2), and by radiotherapist was 10 (range 1–51)
(Figure 3). For surgical consultants, 85 (90%) treated less than 20
new cases per annum, while the corresponding figure for radio-
therapists and oncologists was 14 (67%) seeing less than 20 new
cases per annum.
Times between parts of the process of oral cancer care were
closer to the standards than those for laryngeal cancer (Table 3).
Only two patients (0.4%) were entered into a clinical trial. One
had a quality-of-life score (standard 100%).
422 MA Birchall et al
British Journal of Cancer (2000) 83(4), 421–425 © 2000 Cancer Research Campaign
Table 1 Numbers of new patients presenting with head and neck cancer to
and treated by hospital Trust. The differences in numbers between the two
columns represents those patients who were either transferred to another
hospital for treatment, elected for no treatment or died prior to treatment
Hospital Trust Number Number
(code number) referred treated
13 8 3 8
2– 2
33 6 3 9
41 –
55 4
6– 1
72 7 2 7
86 1
91 1
10 7 3
11 – 1
12 10 9
13 3 3
14 – 1
15 48 49
16 32 34
17 58 65
18 32 31
19 51 56
20 – 1
21 14 14
22 28 27
23 47 59
24 29 30
25 3 2
26 15 12
27 27 34
28 27 23
29 2 1
30 12 8
31 7 6
Private – 6
Refused/none – 6
Table 2 Proportions of new patients with head and neck cancer receiving
radiology pretreatment: chest X-ray (Standard = 100% of all head and neck
cancers should have a chest X-ray); CT-/MRI-scan (Standard = larynx and
oral cancer 90% of T3/T4 tumours, other (ear, nose and sinus) 100%). Rates
by hospital Trust. Some Trusts did not see advanced tumours in some
categories, so the last three columns are blank
Hospital Trust % having chest X-ray  % having scan 
(code number) pretreatment pretreatment
Larynx Oral Other T3/T4 T3/T4 Other
(all) Larynx Oral (ear, nose
and
sinus)
Regional average 51 58 48 55 57 44
Regional range 0–100 0–91 0–100 0–100 0–100
1 59 67 42 67 100 0
2 – – 0 – 100
3 25 64 35 0 44 33
4 – 0 100 – 100
5– – 0 – 0
6 88 60 44 50 80 100
7– – 0 –
8– – 0 –
9 100 – 50 100
10 – – 0 –
11 50 0 67 0
12 100 – 50 –
13 – – 0 –
14 62 60 44 25 44 50
15 15 25 30 100 0 100
16 56 65 70 60 40 43
17 10 80 27 50 80 0
18 94 69 54 50 33 0
19 – 0 – –
20 25 80 20 – 100
21 83 88 54 50 0 40
22 30 32 35 17 100 50
23 86 50 100 100 33
24 – 0 0 –
25 100 40 50 100 50
26 29 91 100 50 100
27 50 50 27 100 100 0
28 0 – – –
29 17 – 0 100
30 – 67 33 – 0
Private – 50 0 – –DISCUSSION
This study demonstrates significant differences between actual
performance and established standards for the process of head and
neck cancer care in the South and West of England in 1996–1997.
When interpreting this data, it is important to note two points.
Firstly, this audit covers new cases only and the actual activity of
the hospitals may be as much as half again due to treatment of
recurrent cancers. It was felt important to concentrate on new cases
only since the ‘first bite at the cherry’ generally represents the best
chance for effective cure or best palliation in patients with head
and neck cancer. Secondly, this data was collected soon after 
the ‘Calman–Hine’ reforms (Calman and Hine, 1995) were
announced, and in many cases, the local head and neck cancer
services have undergone considerable change since the
commencement of data collection in 1996. This includes the amal-
gamation of units in a number of hospitals. Hence, this audit
should not be regarded as a measure of current practice, but rather
that which was occurring at the time. Nonetheless, this represents a
unique bench-marking exercise which allows us to repeat these
measurements with the certain ability of measuring how far we
have come.
Incidences and proportions of tumours in this study matched
those predicted by retrospective cancer registry data (South 
and West Cancer Intelligence Unit, 1996). Completeness of 
data for main and secondary outcome measures was consistently
over 80%.
Staging of head and neck cancers is essential for fully-informed
treatment planning and prognosis, as well as being part of the
necessary minimum data-set for registration and National
Minimum Data-set (Wilson, 1998b; Johnson and Giles, 1999). The
figure of 83% overall staging is in agreement with the 86% of clin-
icians who reported ‘routinely recording’ TNM stage (Edwards et
al, 1997). However, although it is much higher than published
rates of staging for other cancer sites (cervix, 53%) (Jackson et al,
1997; Shepherd and Quirk, 1997), lack of staging information for
the remaining 17% must have severely compromised treatment-
planning for this significant minority.
Only three hospital Trusts treated more than 50 new patients per
annum, while 57% treated less than 20. Of these patients, approxi-
mately half received surgery, either alone or in combination. In
addition, all centres had more than one treating surgeon. This is
reflected in the low numbers of patients treated by most surgical
consultants (median 4, 90% less than 20 per annum). While there
have recently been many debates on how many patients a surgeon
needs to operate on in order to maintain competence, in a complex
area like head and neck cancer infrequent operating may have an
adverse effect on prognosis. Local retrospective data suggest a
10% lower 5-year actuarial survival for patients whose consultant
treats less than 20 patients per annum (Birchall, 1995). However,
lack of staging and co-morbidity information confounds such
analysis, as has been pointed out in a similar study for colorectal
cancer (Kee et al, 1999). Follow-up of the present, well-character-
ized cohort should provide better data on this in a few years’ time.
Very few new patients (2%) in this study were referred to
another hospital Trust for treatment, despite the very large differ-
ences in activity between hospital Trusts. There are many reasons
for this, including financial penalties to the host Trust and, in this
region, geography. Nonetheless, with increasing specialization of
services, facilitated by changes in purchasing, one might expect
this figure to substantially alter in the future.
Only six patients (1.1%) were treated in a private hospital, and
all surgically. Of these, none received complex reconstruction. In
the UK, 5–10% of all operations are performed in the private
sector (BUPA figures), and the low rate for head and neck cancer
probably reflects the low socio-economic grouping of these
patients, as well as the need for complex multidisciplinary care
which is usually only available in NHS hospitals. Inspection of
these very few cases did not show any evidence to support the
hypothesis that treatment selection was any different for those
treated privately.
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Figure 1 Percentages of patients seen in a combined, multidisciplinary
head and neck clinic pretreatment, shown by frequency of clinic. Median and
range shown
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Figure 3 Median number of cases treated per radiotherapist. There were
21 consultant radiotherapists and oncologists with a median number of new
cases of 10 (range 1–51)
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Figure 2 Number of cases treated per surgical consultant. There were 95
surgical consultants with a median of four new patients per consultant (range
1–26)The low proportion of patients receiving a chest X-ray, and low
numbers of patients in many Trusts with advanced disease who
received a CT or MRI scan are in accordance with studies of other
tumour sites. Jackson reports a chest X-ray rate of 42% for patients
in the South West with cervical cancer (Jackson et al, 1997), while
Dickinson reports a figure of 48% for muscle-invasive bladder
cancer (Dickinson et al, 1996). The availability of scanning
machines and reporting expertise may be particularly limited in
smaller Trusts. Nevertheless, as the established standards reflect,
these investigations are fundamental to accurate staging in head
and neck cancer (Houghton et al, 1998).
Times between referral and first attendance at a specialist clinic
are in accordance with published figures for other cancer sites
(Jackson et al, 1997; Martin et al, 1997). The longer times for
laryngeal cancer than for oral cancer may reflect the vaguer nature
of symptoms for many of these patients. Nevertheless, there
remains an important educational message for the general public
and general practitioners about the early warning signs of head and
neck cancer. Overall, times for the parts of the process up to treat-
ment were probably acceptable, and, for radiotherapy, consistent
with the Royal College of Radiologists standards. However, the
very long tail seen for most measurements is not. There is good
biological (Wilson, 1998a) and clinical (Levendag et al, 1996;
Dische et al, 1997) evidence that an increase in the overall time to
and including treatment for head and neck cancer worsens prog-
nosis. At an individual level, more waiting leads to more anxiety
and uncertainty (Richardson, 1998).
It is generally regarded as a fundamental right of the patient
with head and neck cancer to be seen and assessed before treat-
ment planning in a multidisciplinary head and neck clinic (Tobias,
1997; Glaholm, 1997; Wilson, 1998c), and this was reflected in
the standard of 95%. Thus, the overall figure of 45% is deeply
disappointing. It is even lower than the figure suggested by postal
survey (Edwards et al, 1997) where 56% of clinicians said they
‘routinely assessed patients in joint clinics’. The present study also
indicates the enormous variability in the chance of a patient being
seen in such a clinic depending on where they present. A recent
retrospective study from Scotland suggested that the hazard of
recurrent disease, which carries a poor prognosis, is 1.9 times
higher in those patients not assessed in a combined unit
(Robertson et al, 1999). We agree that this pattern of care in a
Western country in the 1990s is ‘astonishing’ (Tobias, 1997).
There was a significant relationship between the frequency of
joint clinics being held and the chances of a new patient at that
hospital Trust being assessed in such a clinic prior to treatment.
While this seems obvious, this result has important implications. It
is inconceivable that all of the hospitals in the present study have
the resources (financial and manpower) to hold weekly, multi-
disciplinary head and neck cancer clinics, with radiotherapist and
oncologist time being at the highest premium (Ryall, 1992). The
inescapable message is, therefore, that only a few hospitals in each
region should hold such clinics and that patients should be referred
to them from other hospitals for a fully-informed, balanced and
timely opinion.
Randomized trials remain the gold standard for demonstrating
improvements in treatment in oncology and are regarded in some
branches of oncology as one of the factors leading to improved
survival figures (Stiller, 1988). However, the present study demon-
strates that this is clearly not the prevailing culture in head and neck
oncology. Only three patients were invited to participate in a clin-
ical trial, and only two were actually recruited. Part of the problem
is the relative rarity of these tumours and in the dilution of care
among so many clinicians. Although the few trials that currently
exist are not universally popular (Tobias et al, 1992), better and
more relevant ones are being designed (Prof J Wilson, personal
communication, 1999). Invitation to participate in a randomized
controlled trial must become ingrained in the culture of head and
neck clinicians, as it has in other areas of oncology (Tobias, 1997).
The lack of measurement of quality-of-life measures at diag-
nosis is equally disappointing, bearing in mind the recent realisa-
tion that conventional outcome measures tell only part of the story.
For head and neck cancer patients, for whom treatment can be
almost de-humanizing at times, it is more important than at any
other cancer site that we correct this deficiency. As with clinical
trials, a culture of considering the patient’s quality of life before,
during and after treatment will facilitate the best care for indi-
vidual patients. There remains uncertainty as to which is the best
of the available tools (Johnson and Giles, 1999, Rogers et al,
1998), but several of them are extremely well-validated and their
use is free (Rogers et al, 1998).
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Table 3 Times between parts of the process of head and neck cancer care in the South and West of England 1996–1997 compared with established
standards: larynx and oral cavity. GP = general practitioner; GDP = general dental practitioner
Larynx Oral cavity
Standard Time between activities Number Actual performance Number Actual performance
assessed for region assessed for region
Median Range Median Range
1 month First symptoms to GP/GDP 159 3 Months 3 days – 100 144 2 months 3 days – 37 months
presentation months
10 days GP/GDP letter to first outpatient 143 21 Days 0–395 days 146 11 days 0–78 days
appointment
No current standard First outpatient appointment to biopsy 113 14 Days 0–354 days 145 2 days 0–431 days
10 days First outpatient appointment to 77 28 days 0–38; 9 days 87 14 days 0–698 days
joint head and neck clinic pretreatment
No current standard First outpatient appointment to 37 26 days 2–114 days 103 29 days 6–727 days
first treatment date (surgery)
No current standard First outpatient appointment to 84 56 days 7–571 days 34 42 days 3–234 days
first treatment date (radiotherapy)It is possible that some of the deficiencies described in this
report have been alleviated by implementation of recommenda-
tions by Trusts and Health Authorities. However, the lack of
central funding to back up the reforms and the innate resistance to
change of many clinicians (Sikora, 1998) makes radical improve-
ments unlikely. In this context, the present data represents an
important means of measuring local performance in this important
area of oncology, facilitating effective clinical governance and
gradual, incremental improvement to the care offered to this, the
most unfortunate, group of cancer patients.
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